DIMming ovarian cancer growth

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1869-1875

  Kandala, Prabodh K ^a   Srivastava, Sanjay K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angiogenesis; Anoikis; Apoptosis; Autophagy; Cisplatin; Diindolylmethane; ER stress; Metastasis; STAT3

Indexed keywords

3, 3' DIINDOLYLMETHANE; CASPASE 3; CISPLATIN; CYCLOHEXIMIDE; CYCLOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 3; INTERLEUKIN 6; JANUS KINASE 2; MITHRAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN IRE1; PROTEIN MCL 1; PROTEIN P62; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANOIKIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL SURVIVAL; DNA DAMAGE; ENDOPLASMIC RETICULUM STRESS; FLOW CYTOMETRY; HUMAN; METASTASIS; NICK END LABELING; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; FEMALE; GROWTH INHIBITORS; HUMANS; INDOLES; OVARIAN NEOPLASMS;

EID: 84879298647     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545650     Document Type: Review

References (80)

1. Cannistra SA. Cancer of the Ovary. Engl J Med 2004; 351(24): 2519-29.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
3. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009; 9(6): 415-28.
4. Bosetti C, Negri E, Franceschi S, et al. Diet and ovarian cancer risk: a case-control study in Italy. Int J Cancer 2001; 93(6): 911-5.
5. Zhang M, Yang ZY, Binns CW, Lee AH. Diet and ovarian cancer risk: a case-control study in China. Br J Cancer 2002; 86(5): 712-7.
6. Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC; Canadian Cancer Registries Epidemiology Research Group. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004; 13(9): 1521-7.
7. Banerjee S, Kong D, Wang Z, Bao B, Hillman GG, Sarkar FH. Attenuation of multi-targeted proliferation-linked signaling by 3,3'- diindolylmethane (DIM): from bench to clinic. Mutation Research. 2011; 728(1-2): 47-66.
8. Ahmad A, Sakr WA, Rahman KW. Mechanisms and Therapeutic Implications of Cell Death Induction by Indole Compounds. Cancers 2011; 3(3): 2955-74.
9. Kandala PK, Srivastava SK. Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol Pharmacol 2010; 78(2): 297-309.
10. Kandala PK, Srivastava SK. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3). BMC Medicine 2012; 10: 9.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74.
12. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408(6811): 433-9.
13. Zhang R, Loganathan S, Humphreys I, Srivastava SK. Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. The J Nutr 2006; 136(11): 2728-34.
14. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8(21): 2540-51.
15. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002; 277(29): 26553-64.
16. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004; 23(16): 2797-808.
17. Scott SP, Pandita TK. The cellular control of DNA double-strand breaks. J Cell Biochem 2006; 99(6): 1463-75.
18. Gong Y, Sohn H, Xue L, Firestone GL, Bjeldanes LF. 3,3'- Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res 2006; 66(9): 4880-7.
19. Choi HJ, Lim do Y, Park JH. Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3'-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol 2009; 9: 39.
20. Hong C, Kim HA, Firestone GL, Bjeldanes LF. 3,3'- Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002; 23(8): 1297-305.
21. Shorey LE, Hagman AM, Williams DE, Ho E, Dashwood RH, Benninghoff AD. 3,3'-Diindolylmethane induces G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells. PloS One 2012; 7(4): e34975.
22. Kandala PK, Wright SE, Srivastava SK. Blocking EGFR activation suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther 2012; 341(1): 24-32.
23. Kandala PK, Srivastava SK. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov Ther 2012; 6(2): 94-101.
24. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology 2002; 181-182: 475-81.
25. Sahu RP, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 2009; 100(9): 1425-33.
26. Hirao A, Cheung A, Duncan G, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 2002; 22(18): 6521-32.
27. Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, et al. Chk2-deficient mice exhibit radioresistance and defective p53- mediated transcription. EMBO J 2002; 21(19): 5195-205.
28. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sciences 2000; 25(10): 496-502.
29. Horvath CM. The Jak-STAT pathway stimulated by interleukin 6. Sci Signal 2004; 2004(260): tr9.
30. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 2000; 79(1): 67-73.
31. Rosen DG, Mercado-Uribe I, Yang G, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006; 107(11): 2730-40.
32. Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011; 17(8): 2538-48.
33. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, et al. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'- diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 2007; 282(29): 21542-50.
34. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007; 67(7): 3310-9.
35. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signa ling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285(1-2): 1-24.
36. Igaz P, Toth S, Falus A. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm Res 2001; 50(9): 435-41.
37. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117(Pt 8): 1281-3.
38. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002; 109 Suppl: S121-31.
39. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2(2): 127-37.
40. Turner T, Chen P, Goodly LJ, Wells A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 1996; 14(4): 409-18.
41. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001; 93(18): 1375-84.
42. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366(1): 2-16.
43. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994; 77(6): 841-52.
44. Palamarchuk VP. [Search for the optimal forms of teaching of roentgenology and radiology at the medical institute]. Vestnik Rentgenologii I Radiologii 1977(1): 88-9.
45. Zheng CF, Guan KL. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J Biol Chem 1993; 268(32): 23933-9.
46. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68(2): 320-44.
47. Wang Y, Kristensen GB, Helland A, Nesland JM, Borresen-Dale AL, Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol 2005; 124(3): 392-401.
48. Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007; 13(2): 143-62.
49. Gao N, Cheng S, Budhraja A, Liu EH, Chen J, Chen D, et al. 3,3'- Diindolylmethane exhibits antileukemic activity in vitro and in vivo through a Akt-dependent process. PloS One 2012; 7(2): e31783.
50. Weng JR, Bai LY, Chiu CF, Wang YC, Tsai MH. The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NFkappaB, MAPK, and p53 signaling. Chem Biol Interact 2012; 195(3): 224-30.
51. Rajoria S, Suriano R, Wilson YL, et al. 3,3'-diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncol Rep 2011; 25(2): 491-7.
52. Katiyar SK. Matrix metalloproteinases in cancer metastasis: molecular targets for prostate cancer prevention by green tea polyphenols and grape seed proanthocyanidins. Endocr Metab Immune Disord Drug Targets 2006; 6(1): 17-24.
53. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003; 22(3): 319-29.
54. Kerbel RS. Tumor Angiogenesis. N Engl J Med 2008; 358(19): 2039-49.
55. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21(3): 505-15.
56. Leong H, Mathur PS, Greene GL. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat 2009; 117(3): 505-15.
57. Lee K, Kang JE, Park SK, et al. LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol 2010; 80(7): 982-9.
58. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67(2): 563-72.
59. Jung JE, Lee HG, Cho IH, et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005; 19(10): 1296-8.
60. Kim EJ, Shin M, Park H, et al. Oral administration of 3,3'- diindolylmethane inhibits lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice. J Nutr 2009; 139(12): 2373-9.
61. Asplund O, Gylbert L, Jurell G. [The American FDA recommends suspension of the use of silicone breast implants]. Lakartidningen 1992; 89(8): 543-5.
62. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115(10): 2656-64.
63. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7(12): 1013-30.
64. Kandala PK, Srivastava SK. Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling Glucose regulatory protein 78 and AMPK. Oncotarget 2012; 3(4): 435-49.
65. Oh SH, Lim SC. Endoplasmic reticulum stress-mediated auto phagy/apoptosis induced by capsaicin (8-methyl-N-vanillyl-6- nonenamide) and dihydrocapsaicin is regulated by the extent of c- Jun NH2-terminal kinase/extracellular signal-regulated kinase activation in WI38 lung epithelial fibroblast cells. J Pharmacol Exp Ther 2009; 329(1): 112-22.
66. Yang PM, Liu YL, Lin YC, Shun CT, Wu MS, Chen CC. Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res 2010; 70(19): 7699-709.
67. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7(12): 961-7.
68. Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of noncanonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ 2008; 15(8): 1318-29.
69. Nishida Y, Arakawa S, Fujitani K, et al. Discovery of Atg5/Atg7- independent alternative macroautophagy. Nature 2009; 461(7264): 654-8.
70. Hoyer-Hansen M, Bastholm L, Szyniarowski P, et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinasebeta, and Bcl-2. Molecular Cell 2007; 25(2): 193-205.
71. Hoyer-Hansen M, Jaattela M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ 2007; 14(9): 1576-82.
72. Abdelrahim M, Newman K, Vanderlaag K, Samudio I, Safe S. 3,3'- diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stressdependent upregulation of DR5. Carcinogenesis 2006; 27(4): 717-28.
73. Fan S, Meng Q, Saha T, Sarkar FH, Rosen EM. Low concen trations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res 2009; 69(15): 6083-91.
74. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5(5): 355-66.
75. Kyriazi S, Kaye SB, deSouza NM. Imaging ovarian cancer and peritoneal metastases--current and emerging techniques. Nat Rev Clin Oncol 2010; 7(7): 381-93.
76. Chien J, Aletti G, Baldi A, et al. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 2006; 116(7): 1994-2004.
77. Buck RC. Walker 256 tumor implantation in normal and injured peritoneum studied by electron microscopy, scanning electron microscopy, and autoradiography. Cancer Res 1973; 33(12): 3181-8.
78. Grossmann J. Molecular mechanisms of detachment-induced apoptosis--Anoikis. Apoptosis 2002; 7(3): 247-60.
79. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008; 272(2): 177-85.
80. Kandala PK, Srivastava SK. Diindolylmethane mediated Gli1 Suppression Induces Anoikis in Ovarian Cancer cells in vitro and blocks tumor formation ability in vivo. J Biol Chem. 2012; 287(34): 28745-54.